A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

- Type of subject: Outpatient

- Informed Consent: A signed and dated written informed consent prior to study
participation.

- Age: Subjects 40 years of age or older at Visit 1.

- Gender: Male or female subjects. A female is eligible to enter and participate in the
study if she is of: Non-child bearing potential (i.e. physiologically incapable of
becoming pregnant, including any female who is post-menopausal or surgically sterile).
Or if of child bearing potential, has a negative pregnancy test at screening, and
agrees to one of the acceptable contraceptive methods mentioned in the protocol used
consistently and correctly:

- Diagnosis: An established clinical history of COPD in accordance with the definition
by the American Thoracic Society/European Respiratory Society as follows: COPD is a
preventable and treatable disease state characterized by airflow limitation that is
not fully reversible. The airflow limitation is usually progressive and is associated
with an abnormal inflammatory response of the lungs to noxious particles or gases,
primarily caused by cigarette smoking. Although COPD affects the lungs, it also
produces significant systemic consequences.

- Smoking history: Current or former cigarette smokers with a history of cigarette
smoking of >=10 pack-years [number of pack years = (number of cigarettes per day/20) x
number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per
day for 20 years)]. Previous smokers are defined as those who have stopped smoking for
at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate
pack year history.

- Severity of disease: A pre and post-salbutamol FEV1/FVC ratio of <0.70 and a
post-salbutamol FEV1 of >=30% and <=70% of predicted normal values calculated using
National Health and Nutrition Examination Survey (NHANES) III reference equations at
Visit 1.

- Dyspnea: A score of >=2 on the Modified Medical Research Council Dyspnea Scale (mMRC)
at Visit 1.

Exclusion Criteria:

- Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
during the study.

- Asthma: A current diagnosis of asthma.

- Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung
infections (such as tuberculosis), and lung cancer are absolute exclusionary
conditions. A subject, who, in the opinion of the investigator, has any other
significant respiratory condition in addition to COPD should be excluded. Examples may
include clinically significant bronchiectasis, pulmonary hypertension, sarcoidosis, or
interstitial lung disease. Inactive tuberculosis in more than one lobe is
exclusionary. Allergic rhinitis is not exclusionary.

- Other Diseases/Abnormalities: Subjects with historical or current evidence of
clinically significant cardiovascular, neurological, psychiatric, renal, hepatic,
immunological, endocrine (including uncontrolled diabetes or thyroid disease) or
hematological abnormalities that are uncontrolled and/or a previous history of cancer
in remission for <5 years prior to Visit 1 (localized carcinoma of the skin that has
been resected for cure is not exclusionary). Significant is defined as any disease
that, in the opinion of the investigator, would put the safety of the subject at risk
through participation, or which would affect the efficacy or safety analysis if the
disease/condition exacerbated during the study.

- Contraindications: A history of allergy or hypersensitivity to any
anticholinergic/muscarinic receptor antagonist, beta2-agonist, corticosteroid,
lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle
glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of
the study physician contraindicates study participation or use of an inhaled
anticholinergic.

- Hospitalization: Hospitalization for pneumonia within 12 weeks prior to Visit 1.

- History of COPD Exacerbation: A documented history of at least one COPD exacerbation
in the 12 months prior to Visit 1 that required either oral corticosteroids,
antibiotics, and/or hospitalization. Prior use of antibiotics alone does not qualify
as an exacerbation history unless the use was associated with treatment of worsening
symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence.

- Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior
to Screening (Visit 1).

- 12-Lead electrocardiogram (ECG): An abnormal and significant ECG finding from the
12-lead ECG conducted at Visit 1. Investigators will be provided with ECG reviews
conducted by a centralized independent cardiologist to assist in evaluation of subject
eligibility.

- Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period
required prior to spirometry testing at each study visit.

- Medications Prior to Screening: Use of the following medications according to the
following defined time intervals prior to Visit 1: Depot corticosteroids - 12 weeks,
Systemic, oral or parenteral corticosteroids - 6 weeks, Antibiotics (for lower
respiratory tract infection) - 6 weeks, Cytochrome P450 3A4 strong inhibitors - 6
weeks, Herbal medications potentially containing oral or systemic steroids - 6 weeks,
Inhaled corticosteroids (ICS) - 30 days, Long-acting beta2-agonist (LABA)/ICS
combination products - 30 days, Phosphodiesterase 4 (PDE4) inhibitors (e.g.,
roflumilast) - 14 days, Inhaled long-acting anticholinergics - 7 days, Olodaterol and
Indacaterol - 10days, Theophyllines - 48 hours, Oral leukotriene inhibitors
(zafirlukast, montelukast, zileuton) - 48 hours, Oral beta2-agonists Long-acting-48
hours/Short-acting - 12 hours, Inhaled long acting beta2-agonists (LABA, e.g.,
salmeterol, formoterol, indacaterol) - 48 hours, Inhaled sodium cromoglycate or
nedocromil sodium - 24 hours, Inhaled short acting beta2-agonists - 4 hours, Inhaled
short-acting anticholinergics - 4 hours, Inhaled short-acting
anticholinergic/short-acting beta2-agonist combination products - 4 hours, Any other
investigational medication - 30 days or within 5 drug half-lives (whichever is
longer).

- Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed
for greater than 12 hours a day. As-needed oxygen use (i.e., <=12 hours per day) is
not ex-clusionary.

- Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use)
of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.

- Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary
rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the
maintenance phase of a pulmonary rehabilitation program are not excluded.

- Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2
years prior to Visit 1.

- Affiliation with Investigator Site: A subject will not be eligible for this study if
he/she is an immediate family member of the participating investigator,
sub-investigator, study coordinator, or employee of the participating investigator.

- Inability to read: A subject will not be eligible for the study if in the opinion of
the investigator the subject cannot read.